About this trial
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Eligibility criteria
Qualifiers
Self-identifies as Black or African American
Age ≥35 to ≤80 years old
CKD Stage 1-4
Self-reported 6 or more hours/day of sedentary time
Disqualifiers
Being unable to walk 1 block
Being unable to stand from a seated position without assistance
Using a wheelchair, walker, or cane for all of their ambulation
Presence of a condition(s) or diagnosis, either physical or psychological, that precludes participation, including: Lower-extremity amputation (AKA or BKA) without prosthetic, Orthopedic condition that would preclude prompted sit-to-stand transitions or standing, Neurologic or psychiatric condition that would preclude prompted sit-to- stand transitions or standing, Severe cognitive impairment, Unstable coronary artery disease (i.e., angina with activity), Orthostatic hypotension
Trial design
Treatments tested in this trial
- RESET-CKD
- Attention Control
Treatment groups
Sponsors and collaborators
University of Illinois at Chicago
Lead sponsor
National Institute of Nursing Research (NINR)
Collaborator